Efficacy and Mechanism of the Jiangtang Tiaozhi Recipe in the Management of Type 2 Diabetes and Dyslipidaemia: A Clinical Trial Protocol

Haoran Wu, Xinyi Fang, De Jin, Runyu Miao, Jiahua Wei, Tianyu Zhao, Dan Dai, Jiangquan Liao, Jia Wang, Fengmei Lian, Jiaxing Tian, Haoran Wu, Xinyi Fang, De Jin, Runyu Miao, Jiahua Wei, Tianyu Zhao, Dan Dai, Jiangquan Liao, Jia Wang, Fengmei Lian, Jiaxing Tian

Abstract

Background: Type 2 diabetes mellitus (T2DM) complicated with dyslipidaemia is associated with a high risk of cardiovascular diseases. The Jiangtang Tiaozhi (JTTZ) recipe is a Chinese herbal formula that has been used to regulate the blood glucose and lipid levels for many years. Interestingly, a previous study has demonstrated its efficacy; however, the associated mechanism remains unclear. We hypothesised that the therapeutic effect of the JTTZ on patients with T2DM may be mediated by the modulation of metabolites secreted by the gut microbiota. This study aims to examine this mechanism. Methods and analysis: This study is a randomised, positive drug parallel-controlled, open-label clinical trial in patients with T2DM and dyslipidaemia. A total of 96 patients will be recruited and randomly assigned to treatment with JTTZ or metformin for 12 weeks. The primary outcome will be the rates of effectively regulated blood glucose and lipid levels (measured with the levels of glycated haemoglobin, fasting plasma glucose, 2-h plasma glucose, triglyceride, and low-density lipoprotein cholesterol). The secondary outcomes will be the changes in body weight, body mass index, and waist circumference and Traditional Chinese Medicine symptom scores. In addition, 16S rRNA gene sequencing will be performed on the gut microbiota obtained from faeces, and metabolomics analysis will be performed based on blood and gut microbiota samples. Intention-to-treat, per-protocol analysis and safety analysis will be performed. Clinical trial registration number: https://ichgcp.net/clinical-trials-registry/NCT04623567.

Keywords: Jiangtang Tiaozhi recipe; clinical trial protocol; dyslipidaemia; herbal medicine; type 2 diabetes.

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2022 Wu, Fang, Jin, Miao, Wei, Zhao, Dai, Liao, Wang, Lian and Tian.

Figures

FIGURE 1
FIGURE 1
Flow diagram of the study design.

References

    1. American Diabetes Association (2020). 10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes-2020. Diabetes care 43 (Suppl. 1), S111–S134. 10.2337/dc20-S010
    1. American Diabetes Association (2019). 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2019. Diabetes Care 42 (Suppl. 1), S90–s102. 10.2337/dc19-S009
    1. Chan A. W., Tetzlaff J. M., Gøtzsche P. C., Altman D. G., Mann H., Berlin J. A., et al. (2013). SPIRIT 2013 Explanation and Elaboration: Guidance for Protocols of Clinical Trials. BMJ 346, e7586. 10.1136/bmj.e7586
    1. China Diabetes Society (2021). Guideline for the Prevention and Treatment of Type 2 Diabetes Mellitus in China (2020 Edition). Chin. J. Endocrinol. Metab. 37 (04), 311–398. 10.3760/cma.j.cn311282-20210304-00142
    1. Chinese Joint Committee for Developing Chinese Guidelines on Prevention and Treatment of Dyslipidemia in Adults (2016). Chinese Guidelines on Prevention and Treatment of Dyslipidemia in Adults. Chin. Circ. J. 31 (10), 937–953. 10.3969/j.issn.1000-3614.2016.10.001
    1. Eliasson B., Cederholm J., Eeg-Olofsson K., Svensson A. M., Zethelius B., Gudbjörnsdottir S. (2011). Clinical Usefulness of Different Lipid Measures for Prediction of Coronary Heart Disease in Type 2 Diabetes: a Report from the Swedish National Diabetes Register. Diabetes care 34 (9), 2095–2100. 10.2337/dc11-0209
    1. Gerstein H. C., Pogue J., Mann J. F., Lonn E., Dagenais G. R., McQueen M., et al. (2005). The Relationship between Dysglycaemia and Cardiovascular and Renal Risk in Diabetic and Non-diabetic Participants in the HOPE Study: a Prospective Epidemiological Analysis. Diabetologia 48 (9), 1749–1755. 10.1007/s00125-005-1858-4
    1. Gurung M., Li Z., You H., Rodrigues R., Jump D. B., Morgun A., et al. (2020). Role of Gut Microbiota in Type 2 Diabetes Pathophysiology. EBioMedicine 51, 102590–90. 10.1016/j.ebiom.2019.11.051
    1. Jia W., Weng J., Zhu D., Ji L., Lu J., Zhou Z., et al. (2019). Standards of Medical Care for Type 2 Diabetes in China 2019. Diabetes Metab. Res. Rev. 35 (6), e3158. 10.1002/dmrr.3158
    1. Kuno T., Hirayama-Kurogi M., Ito S., Ohtsuki S. (2018). Reduction in Hepatic Secondary Bile Acids Caused by Short-Term Antibiotic-Induced Dysbiosis Decreases Mouse Serum Glucose and Triglyceride Levels. Sci. Rep. 8 (1), 1253. 10.1038/s41598-018-19545-1
    1. Li Y., Teng D., Shi X., Qin G., Qin Y., Quan H., et al. (2020). Prevalence of Diabetes Recorded in mainland China Using 2018 Diagnostic Criteria from the American Diabetes Association: National Cross Sectional Study. BMJ 369, m997. 10.1136/bmj.m997
    1. Lian F., Ni Q., Shen Y., Yang S., Piao C., Wang J., et al. (2020). International Traditional Chinese Medicine Guideline for Diagnostic and Treatment Principles of Diabetes. Ann. Palliat. Med. 9 (4), 2237–2250. 10.21037/apm-19-271
    1. Pan L., Yang Z., Wu Y., Yin R. X., Liao Y., Wang J., et al. (2016). The Prevalence, Awareness, Treatment and Control of Dyslipidemia Among Adults in China. Atherosclerosis 248, 2–9. 10.1016/j.atherosclerosis.2016.02.006
    1. Petrie J. R., Rossing P. R., Campbell I. W. (2020). Metformin and Cardiorenal Outcomes in Diabetes: A Reappraisal. Diabetes Obes. Metab. 22 (6), 904–915. 10.1111/dom.13984
    1. Sanna S., van Zuydam N. R., Mahajan A., Kurilshikov A., Vich Vila A., Võsa U., et al. (2019). Causal Relationships Among the Gut Microbiome, Short-Chain Fatty Acids and Metabolic Diseases. Nat. Genet. 51 (4), 600–605. 10.1038/s41588-019-0350-x
    1. Tong X., Xu J., Lian F., Yu X., Zhao Y., Xu L., et al. (2018). Structural Alteration of Gut Microbiota during the Amelioration of Human Type 2 Diabetes with Hyperlipidemia by Metformin and a Traditional Chinese Herbal Formula: a Multicenter, Randomized, Open Label Clinical Trial. mBio 9 (3). 10.1128/mBio.02392-17
    1. Turner R. C., Millns H., Neil H. A., Stratton I. M., Manley S. E., Matthews D. R., et al. (1998). Risk Factors for Coronary Artery Disease in Non-insulin Dependent Diabetes Mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). BMJ 316 (7134), 823–828. 10.1136/bmj.316.7134.823
    1. Wilson P. W., D'Agostino R. B., Levy D., Belanger A. M., Silbershatz H., Kannel W. B. (1998). Prediction of Coronary Heart Disease Using Risk Factor Categories. Circulation 97 (18), 1837–1847. 10.1161/01.cir.97.18.1837
    1. Wu H., Tian J., Dai D., Liao J., Wang X., Wei X., et al. (2020). Efficacy and Safety Assessment of Traditional Chinese Medicine for Metabolic Syndrome. BMJ Open Diabetes Res. Care 8 (1). 10.1136/bmjdrc-2020-001181
    1. Xu J., Lian F., Zhao L., Zhao Y., Chen X., Zhang X., et al. (2015). Structural Modulation of Gut Microbiota during Alleviation of Type 2 Diabetes with a Chinese Herbal Formula. Isme j 9 (3), 552–562. 10.1038/ismej.2014.177
    1. Xu T., Brandmaier S., Messias A. C., Herder C., Draisma H. H., Demirkan A., et al. (2015). Effects of Metformin on Metabolite Profiles and LDL Cholesterol in Patients with Type 2 Diabetes. Diabetes Care 38 (10), 1858–1867. 10.2337/dc15-0658
    1. Yan L., Xu M. T., Yuan L., Chen B., Xu Z. R., Guo Q. H., et al. (2016). Prevalence of Dyslipidemia and its Control in Type 2 Diabetes: A Multicenter Study in Endocrinology Clinics of China. J. Clin. Lipidol. 10 (1), 150–160. 10.1016/j.jacl.2015.10.009
    1. Yu X., Xu L., Zhou Q., Wu S., Tian J., Piao C., et al. (2018). The Efficacy and Safety of the Chinese Herbal Formula, JTTZ, for the Treatment of Type 2 Diabetes with Obesity and Hyperlipidemia: A Multicenter Randomized, Positive-Controlled, Open-Label Clinical Trial. Int. J. Endocrinol. 2018, 9519231. 10.1155/2018/9519231
    1. Zhao X. (2013). The Efficacy Analysis of Jiangtangtiaozhi Formula in Reducing Blood Glucose, Lipid and Weight of Type 2 Diabetes Patients [Master of Medicine]. Beijing: China Academy of Chinese Medical Sciences.

Source: PubMed

Sponsorer och medarbetare

Medicinska tillstånd

Läkemedelsinterventioner

3
Prenumerera